Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Topscience Biotech specializes in R&D, production, sales of Sodium Hyaluronate, focusing on Cosmetics, Medical, Pharmaceutical Grade HA

    Virtual Booth

    Contact Supplier

    Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    China

    Virtual Booth

    Contact Supplier

    Menu

    Elamipretide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Stealth to Cut Jobs After FDA Rejects Therapy for Rare Disorder
    Stealth to Cut Jobs After FDA Rejects Therapy for Rare Disorder

    29 May 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-asks-stealth-biotherapeutics-resubmit-application-rare-genetic-condition-2025-05-29/

    REUTERS
    29 May 2025
    Share Share
    Barth Syndrome Foundation Urges FDA Action on Elamipretide Delay
    Barth Syndrome Foundation Urges FDA Action on Elamipretide Delay

    29 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250429986004/en/Barth-Syndrome-Foundation-Calls-for-Urgent-FDA-Action-Following-Elamipretide-Delay

    BUSINESSWIRE
    29 Apr 2025
    Share Share
    FDA Advisory Committee To Review Stealth's Elamipretide For Barth Syndrome
    FDA Advisory Committee To Review Stealth's Elamipretide For Barth Syndrome

    09 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-fda-advisory-committee-meeting-to-review-elamipretide-for-barth-syndrome-treatment-302242393.html

    PR NEWSWIRE
    09 Sep 2024
    Share Share
    Stealth BioTherapeutics Completes Mid-Cycle Review For Elamipretide In Barth
    Stealth BioTherapeutics Completes Mid-Cycle Review For Elamipretide In Barth

    29 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/stealth-biotherapeutics-completes-mid-cycle-review-meeting-on-elamipretide-for-the-treatment-of-barth-syndrome-302207846.html

    PR NEWSWIRE
    29 Jul 2024
    Share Share
    Stealth Bio: First Patient In Phase 3 Elamipretide For Dry AMD
    Stealth Bio: First Patient In Phase 3 Elamipretide For Dry AMD

    05 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-first-patient-enrolled-in-global-phase-3-clinical-program-for-elamipretide-in-patients-with-dry-age-related-macular-degeneration-302164947.html

    PR NEWSWIRE
    05 Jun 2024
    Share Share
    Stealth Biotherapeutics' Barth Syndrome NDA Receives Priority Review Designation
    Stealth Biotherapeutics' Barth Syndrome NDA Receives Priority Review Designation

    07 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/stealth-biotherapeutics-barth-syndrome-nda-receives-priority-review-designation-302138192.html

    PR NEWSWIRE
    07 May 2024
    Share Share